Table 1 Current RTOG head and neck protocols requiring larynx contours
From: Development of a standardized method for contouring the larynx and its substructures
Protocol | Constraint | Contouring instructions |
|---|---|---|
RTOG 1016: Phase III trial of radiotherapy plus cetuximab vs chemoradiotherapy in HPV-positive oropharynx cancer | Reduce the dose as much as possible | GSL: "triangular prism-shaped" volume that begins just inferior to the hyoid bone and extends to the cricoid cartilage inferiorly and extends from the anterior commissure to include the arytenoids. This includes the infrahyoid but not the suprahyoid epiglottis |
Glottic larynx mean dose ≤ 20 Gy (2Gy/fx) | ||
RTOG 1008: Phase II study of adjuvant concurrent radiation and chemotherapy vs radiation alone in resected high-risk malignant salivary gland tumors | Reduce the dose as much as possible Larynx mean dose <35 Gy whenever feasible (2 Gy/fx) | Same as RTOG 1016 |
RTOG 0920: Phase III study of postoperative radiation therapy +/− cetuximab for locally advanced resected head and neck cancer | Reduce the dose as much as possible Larynx mean dose <45 Gy whenever feasible (2 Gy/fx) | Same as RTOG 1016 |
RTOG 0912: Phase II study of concurrent intensity-modulated radiation therapy, paclitaxel, and pazopanib/placebo, for the treatment of anaplastic thyroid cancer | Glottic larynx mean dose <60 Gy (2Gy/fx) | None provided |